{
    "xml": "<topic id=\"PHP81535\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/gardasil\" basename=\"gardasil\" title=\"Gardasil\">\n<title>Gardasil<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP81946\" outputclass=\"indicationsAndDose\" rev=\"1.39\" parent=\"/clinical-medicinal-product-information/gardasil\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of premalignant genital (cervical, vulvar and vaginal) and anal lesions, cervical and anal cancers, and genital warts</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child female\">\n<p>Child 9&#8211;17 years (female)</p>\n<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8239;month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5&#8239;mL after 3&#8239;months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.</p>\n</li>\n<li outputclass=\"patientGroup adult female\">\n<p>Adult (female)</p>\n<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8239;month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5&#8239;mL after 3&#8239;months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of premalignant genital (cervical, vulvar, and vaginal) and anal lesions, cervical and anal cancers, and genital warts (alternative schedule)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child female\">\n<p>Child 9&#8211;13 years (female)</p>\n<p>0.5&#8239;mL, for 1 dose, followed by 0.5&#8239;mL after 6&#8239;months for 1 dose, if the second dose is administered earlier than 6 months after the first dose, a third dose should be administered, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81535",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/gardasil",
    "basename": "gardasil",
    "title": "Gardasil",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prevention of premalignant genital (cervical, vulvar and vaginal) and anal lesions, cervical and anal cancers, and genital warts",
                        "html": "Prevention of premalignant genital (cervical, vulvar and vaginal) and anal lesions, cervical and anal cancers, and genital warts"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child female": [
                    {
                        "textContent": "0.5 mL for 1 dose, followed by 0.5 mL after 1 month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL after 3 months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.",
                        "html": "<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8239;month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5&#8239;mL after 3&#8239;months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.</p>",
                        "ageGroup": "child 9&#8211;17 years (female)"
                    }
                ],
                "adult female": [
                    {
                        "textContent": "0.5 mL for 1 dose, followed by 0.5 mL after 1 month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL after 3 months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.",
                        "html": "<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8239;month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5&#8239;mL after 3&#8239;months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.</p>",
                        "ageGroup": "adult (female)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of premalignant genital (cervical, vulvar, and vaginal) and anal lesions, cervical and anal cancers, and genital warts (alternative schedule)",
                        "html": "Prevention of premalignant genital (cervical, vulvar, and vaginal) and anal lesions, cervical and anal cancers, and genital warts (alternative schedule)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child female": [
                    {
                        "textContent": "0.5 mL, for 1 dose, followed by 0.5 mL after 6 months for 1 dose, if the second dose is administered earlier than 6 months after the first dose, a third dose should be administered, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more.",
                        "html": "<p>0.5&#8239;mL, for 1 dose, followed by 0.5&#8239;mL after 6&#8239;months for 1 dose, if the second dose is administered earlier than 6 months after the first dose, a third dose should be administered, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more.</p>",
                        "ageGroup": "child 9&#8211;13 years (female)"
                    }
                ]
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}